Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionIKur antagonist
Molecular Target Potassium channel Kv1.5 (KCNA5)
Mechanism of ActionPotassium channel Kv1.5 (KCNA5) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationFibrillation
Indication DetailsTreat atrial fibrillation
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today